Document is current
Any future updates will be listed below
-
Authors
Ogliari, Francesca Rita https://orcid.org/0000-0003-1594-2407
Jongbloed, Mandy https://orcid.org/0000-0003-4686-9169
Vaes, Rianne D. W. https://orcid.org/0000-0001-6812-2897
Houben, Ruud M. A. https://orcid.org/0000-0001-6869-9733
Bartolomeo, Valentina https://orcid.org/0009-0007-1493-7282
van den Borne, Ben E. E. M.
Degens, Juliette https://orcid.org/0000-0003-0279-9656
Huijs, Jarno W. J. https://orcid.org/0000-0001-9117-6885
Pitz, Cordula
Steens, Michelle
Youssef-El Soud, Magdolen
Sollini, Martina https://orcid.org/0000-0003-2214-6492
De Ruysscher, Dirk K. M.
Mitea, Cristina https://orcid.org/0000-0001-5885-957X
Hendriks, Lizza E. L. https://orcid.org/0000-0002-3521-2535
-
Funding
Funding for this research was provided by:
Wassink Hesp Foundation (Wassink Hesp Foundation)
Pfizer Pharmaceuticals (88250917)
- License Information
-
More Information
Article History
Received: 4 July 2025
Accepted: 27 August 2025
First Online: 10 October 2025
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Maastricht UMC + institutional review board (2021–2973) and the local IRBs of the participating hospitals.
: Informed consent was waived by Maastricht UMC + institutional review board (2021–2973) and the local IRBs of the participating hospitals.
: FO received fees as speaker from Roche Genentech, Sanofi, Amgen, and travel support from Amgen, Johnson&Johnson.MS received speaker honoraria from Elma academy, Train srl, Accademia nazionale di medicina, GE Healthcare, and serves as associate editor of Cancer Imaging for the “Artificial intelligence, machine learning and radiomics” section.DDR received research grants, financial supports and/or participated at advisory boards of AstraZeneca, BMS, Beigene, Philips, Olink, Eli-Lilly; all should be considered institutional financial interests (not personal).LH received research funding from Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda, Merck, Pfizer, Novartis, Gilead; all payments were paid to the institution. LH received fees as speaker at educationals or webinars from AstraZeneca, Bayer, Lilly, MSD, high5oncology, Takeda, Janssen, GSK, Sanofi, Pfizer (Inst), Medtalks, Benecke, VJOncology, Medimix; all payments were paid to the institution with the exception of Medtalks, Benecke, VJOncology, Medimix. LH participated at advisory boards of Abbvie, Amgen, Anhearth, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi, GSK, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Summit Therapeutics, Takeda; all payments were paid to the institution. LH is member of guideline committees for Dutch guidelines on NSCLC, brain metastases and leptomeningeal metastases (payment to self), ESMO guidelines on metastatic NSCLC, non-metastatic NSCLC and SCLC (non-financial); other roles: secretary NVALT studies foundation, subchair EORTC metastatic NSCLC systemic therapy, vice-chair scientific committee Dutch Thoracic Group. LH is local principal investigator of clinical trials funded by AstraZeneca, GSK, Novartis, Merck, Roche, Takeda, Blueprint, Mirati, Abbvie, Gilead, MSD, Merck, Amgen, Boehringer Ingelheim, Pfizer.The other authors have no relevant financial or non-financial interests to disclose.
: Not applicable.
